CCSG P30 Administrative Supplement Opportunities Available from the NCI Division of Cancer Control and Population Sciences (DCCPS)

March 24, 2023

DF/HCC has received from NCI three separate P30 supplement opportunities from the NCI Division of Cancer Control and Population Sciences (DCCPS). This year supplements can be submitted through the P30 Cancer Center Support Grant or other grant mechanisms listed in the attached announcements.

We will conduct an internal review at DF/HCC to select a single P30 project for each opportunity. PLEASE NOTE: If you have a project you would like considered for one of these applications, please submit the following information by e-mail to Deborah Goff, no later than 3/29/23: 

  • Name, academic title, institutional affiliation
  • Supplement Opportunity for which you would like to be considered (1, 2 or 3 below)
  • Project title plus one-to-two-page description of project
  • NIH biosketch for key project personnel

Investigators will be notified during the week of 4/3/23 if their project has been selected for the supplement application.


1. Administrative supplements to examine the effects of digital tools and interventions on patient-provider communication across the cancer control continuum 

(Read the full RFA here) 

  • Application due 4/21/23 

  • This administrative supplement allows currently funded NCI extramural investigators to examine the effects of digital tools/interventions on patient-provider communication and/or how patient-provider communication influences the relationships between digital tools/interventions and cancer-related outcomes of interest to the parent study. Applicants may propose to supplement parent awards that are focused on the development, testing, or delivery of digital health tools/interventions or to explore digital health-related barriers or opportunities in their patient-provider communication focused research. 
  • One year of funding, up to $100K (Total Costs) 

2. Administrative Supplement to Support Health Policy Research in Cancer Prevention and Control 

(Read the full RFA here) 

  • Application due 4/21/23 

  • There are two areas of focus for this opportunity. Applicants must choose either Option 1 or Option 2; applications may NOT address both options. 
    • Option 1: Empirical analysis of associations between cancer-related health policies and outcomes. Projects can propose to generate and analyze data on federal or state policies that impact cancer control including, but not limited to, broad legislation or regulations that impact eligibility for publicly subsidized health insurance, premium cost of private insurance, health insurance benefit design, provider reimbursement, cost sharing, or healthcare financing. Outcomes of interest include, but are not limited to, cancer-related healthcare access, utilization, quality, total or out-of-pocket expenditure, financial hardship, quality of life, patient care experience, and survival. 
    • Option 2: Community-engaged dissemination or implementation (D&I) research. Projects can leverage community partnerships (e.g., with cancer control coalitions, community-based organizations, state health departments, etc.) to advance the dissemination of scientific evidence to inform the development of policies that will positively impact health, to disseminate evidence on health policies known to be effective in promoting cancer control, or to study implementation of an evidence-based cancer control policy in a new context relevant to community needs. 
  • One year of funding, up to $125K (Total Costs) 

3. Administrative supplements to conduct systematic evidence reviews on the clinical utility of cancer-site specific polygenic risk scores (PRS) for cancer risk assessment 

(Read the full RFA here) 

  • Application due 4/21/23 

  • The research objective of this opportunity is to conduct a systematic evidence review on the clinical utility (CU) of cancer-site specific polygenic risk scores (PRS) for cancer risk assessment. (PRS for cancer prognosis should not be included in the systematic reviews.) The review should include a detailed description and discussion of cancer-site-specific PRS with respect to their development and validation and describe what is known about the efficacy and/or effectiveness of their application for guiding risk management, and potential harms and benefits associated with the clinical use of PRS. In addition, the review should propose criteria for which PRS are candidates for evaluation of CU through clinical trials and discuss the optimal study designs and methods to assess efficacy and effectiveness.  The review should emphasize issues and challenges as it relates to evaluating the CU of PRS for significant clinical and public health outcomes including descriptions of ongoing and proposed research studies. 
  • One year of funding, up to $150K (Total Costs) 

Related files